Rice Hall James & Associates LLC Sells 2,885 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Rice Hall James & Associates LLC cut its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 0.9% during the 3rd quarter, Holdings Channel reports. The fund owned 306,635 shares of the medical instruments supplier’s stock after selling 2,885 shares during the period. Rice Hall James & Associates LLC’s holdings in AngioDynamics were worth $2,386,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Quarry LP boosted its stake in AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 2,594 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in AngioDynamics by 9.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock worth $199,000 after buying an additional 2,821 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in AngioDynamics by 44.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 4,780 shares during the last quarter. CWM LLC raised its holdings in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics during the third quarter worth $86,000. 89.43% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO James C. Clemmer acquired 20,000 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was bought at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the transaction, the chief executive officer now owns 681,582 shares of the company’s stock, valued at $4,109,939.46. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders bought 22,568 shares of company stock worth $135,847. 5.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ANGO shares. Canaccord Genuity Group lowered their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research report on Friday, October 4th.

AngioDynamics Trading Down 0.1 %

ANGO stock opened at $6.68 on Friday. The firm has a 50 day moving average of $7.07 and a 200-day moving average of $6.69. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $8.25. The firm has a market capitalization of $271.41 million, a P/E ratio of -1.10 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. During the same period last year, the business earned ($0.12) earnings per share. AngioDynamics’s revenue was down 14.2% compared to the same quarter last year. Sell-side analysts predict that AngioDynamics, Inc. will post -0.41 EPS for the current year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.